116 related articles for article (PubMed ID: 30481381)
1. Hypomethylation of mismatch repair genes MLH1 and MSH2 is associated with chemotolerance of breast carcinoma: Clinical significance.
Dasgupta H; Islam S; Alam N; Roy A; Roychoudhury S; Panda CK
J Surg Oncol; 2019 Jan; 119(1):88-100. PubMed ID: 30481381
[TBL] [Abstract][Full Text] [Related]
2. Induction of HRR genes and inhibition of DNMT1 is associated with anthracycline anti-tumor antibiotic-tolerant breast carcinoma cells.
Dasgupta H; Islam MS; Alam N; Roy A; Roychoudhury S; Panda CK
Mol Cell Biochem; 2019 Mar; 453(1-2):163-178. PubMed ID: 30178275
[TBL] [Abstract][Full Text] [Related]
3. Differential operation of MLH1/MSH2 and FANCD2 crosstalk in chemotolerant bladder carcinoma: a clinical and therapeutic intervening study.
Basu M; Mukhopadhyay D; Chakraborty B; Ghosh S; Pal DK; Ghosh A; Panda CK
Mol Cell Biochem; 2023 Jul; 478(7):1599-1610. PubMed ID: 36434146
[TBL] [Abstract][Full Text] [Related]
4. Frequent alterations of homologous recombination repair pathway in primary and chemotolerant breast carcinomas: clinical importance.
Dasgupta H; Mukherjee N; Islam S; Bhattacharya R; Alam N; Roy A; Roychoudhury S; Biswas J; Panda CK
Future Oncol; 2017 Jan; 13(2):159-174. PubMed ID: 27646721
[TBL] [Abstract][Full Text] [Related]
5. Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance.
Kaplan E; Gündüz U
Biomed Pharmacother; 2012 Feb; 66(1):29-35. PubMed ID: 22285073
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
[TBL] [Abstract][Full Text] [Related]
7. Reduction of nuclear Y654-p-β-catenin expression through SH3GL2-meditated downregulation of EGFR in chemotolerance TNBC: Clinical and prognostic importance.
Islam MS; Dasgupta H; Basu M; Roy A; Alam N; Roychoudhury S; Kumar Panda C
J Cell Physiol; 2020 Nov; 235(11):8114-8128. PubMed ID: 31960967
[TBL] [Abstract][Full Text] [Related]
8. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
9. Association between promoter methylation of MLH1 and MSH2 and reactive oxygen species in oligozoospermic men-A pilot study.
Gunes S; Agarwal A; Henkel R; Mahmutoglu AM; Sharma R; Esteves SC; Aljowair A; Emirzeoglu D; Alkhani A; Pelegrini L; Joumah A; Sabanegh E
Andrologia; 2018 Apr; 50(3):. PubMed ID: 28983945
[TBL] [Abstract][Full Text] [Related]
10. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of mutS homolog 2 and mutL homolog 1 affects overall survival in laryngeal squamous cell carcinoma patients: Investigation into a potential cause.
Gong HL; Shi Y; Shi Y; Wu CP; Cao PY; Zhou L; Xu C
Oncol Rep; 2013 Sep; 30(3):1371-9. PubMed ID: 23787767
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung.
Gomes A; Reis-Silva M; Alarcão A; Couceiro P; Sousa V; Carvalho L
Rev Port Pneumol; 2014; 20(1):20-30. PubMed ID: 24360395
[TBL] [Abstract][Full Text] [Related]
13. Expressional analysis of MLH1 and MSH2 in breast cancer.
Malik SS; Masood N; Asif M; Ahmed P; Shah ZU; Khan JS
Curr Probl Cancer; 2019 Apr; 43(2):97-105. PubMed ID: 30149959
[TBL] [Abstract][Full Text] [Related]
14. Role of MLH1 and MSH2 deficiency in the development of tumorigenesis and chemo-tolerance of cervical Carcinoma: Clinical implications.
Dutta P; Pal D; Roy A; Mandal RK; Panda CK
Gene; 2023 Dec; 888():147746. PubMed ID: 37657688
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair and treatment resistance in ovarian cancer.
Helleman J; van Staveren IL; Dinjens WN; van Kuijk PF; Ritstier K; Ewing PC; van der Burg ME; Stoter G; Berns EM
BMC Cancer; 2006 Jul; 6():201. PubMed ID: 16879751
[TBL] [Abstract][Full Text] [Related]
16. The expression of MLH1 and MSH2 genes among inhabitants of high background radiation area of Ramsar, Iran.
Bakhtiari E; Monfared AS; Niaki HA; Borzoueisileh S; Niksirat F; Fattahi S; Monfared MK; Gorji KE
J Environ Radioact; 2019 Nov; 208-209():106012. PubMed ID: 31323602
[TBL] [Abstract][Full Text] [Related]
17. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
[TBL] [Abstract][Full Text] [Related]
18. Exonic deletions of mismatch repair genes MLH1 and MSH2 correlate with prognosis and protein expression levels in malignant melanomas.
Korabiowska M; Brinck U; Stachura J; Jawien J; Hasse FM; Cordon-Cardos C; Fischer G
Anticancer Res; 2006; 26(2A):1231-5. PubMed ID: 16619529
[TBL] [Abstract][Full Text] [Related]
19. Repair genes expression profile of MLH1, MSH2 and ATM in the normal oral mucosa of chronic smokers.
Alves MG; Carta CF; de Barros PP; Issa JS; Nunes FD; Almeida JD
Arch Oral Biol; 2017 Jan; 73():60-65. PubMed ID: 27693945
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability and promoter hypermethylation of MLH1 and MSH2 in patients with sporadic colorectal cancer.
Vlaykova T; Mitkova A; Stancheva G; Kadiyska T; Gulubova M; Yovchev Y; Cirovski G; Chilingirov P; Damyanov D; Kremensky I; Mitev V; Kaneva R
J BUON; 2011; 16(2):265-73. PubMed ID: 21766496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
